antibody

Anti-TACE, Recombinant [D1 (A12)]

152045

polyclonal

human

nonconjugated

6868

152045

Fn

TACE (ADAM17)

Human

TACE (CD156b) has proved capable of cleaving epidermal growth factor receptor (EGFR) ligands, extracellular Notch1, cell-surface receptors, and adhesion molecules. As proteolytic cleavage is an indispensable activation event for many of these substrates, TACE has emerged as an attractive therapeutic target for the treatment of cancer and rheumatoid arthritis. This “cross-domain” human antibody is a selective TACE antagonist and provides a unique alternative to smallmolecule metalloprotease inhibition.

Human

Recombinant human ADAM17 (TACE) ectodomain tagged to biotin.

IgG1

Brain, heart, kidney, liver, lung and spleen

Cancer, Cell Signaling & Signal Transduction, Metabolism, Neurobiology, Stem Cell Biology

ADAM multidomain topology was exploited by first isolating an inhibitory human antibody (D1) that bound TACE-specific noncatalytic regions exclusively through its variable heavy (VH) domain. A D1-VH biased scFv phage-display library was then used to selectively isolate a new variable light (VL) chain that could simultaneously bind to the TACE catalytic domain. The resulting “cross-domain” human IgG1 antibody [D1(A12)] is a previously undescribed biochemically holistic ADAM ectodomain inhibitor and demonstrates a unique alternative to small-molecule metalloprotease inhibition. D1(A12) only binds to the human form of TACE not to mouse. Ki: 0.27+/- 0.03nM against hADAM17. Note from inventor: "D1(A12) is conformation sensitive and sees only a specific form of the native enzyme (reflecting its redox state). It does not work by IHC or WB. It was designed as a potential drug, active in native situations".

PBS

5.9mg/ml